Refine
Year of publication
Language
- English (1132)
Has Fulltext
- yes (1132)
Is part of the Bibliography
- no (1132)
Keywords
- BESIII (17)
- Heavy Ion Experiments (13)
- e +-e − Experiments (12)
- Hadron-Hadron Scattering (11)
- Branching fraction (9)
- LHC (9)
- Particle and Resonance Production (8)
- Quarkonium (6)
- Hadronic decays (5)
- Spectroscopy (5)
- ALICE experiment (4)
- Branching fractions (4)
- Charm Physics (4)
- Charm physics (4)
- Collective Flow (4)
- Jets (4)
- Lepton colliders (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Charmed mesons (3)
- Charmonium (3)
- Elastic scattering (3)
- Electroweak interaction (3)
- Exotics (3)
- Experimental nuclear physics (3)
- Experimental particle physics (3)
- Hadron-Hadron scattering (experiments) (3)
- Heavy Quark Production (3)
- Heavy-ion collision (3)
- Initial state radiation (3)
- Jets and Jet Substructure (3)
- Polarization (3)
- QCD (3)
- e+-e− Experiments (3)
- pp collisions (3)
- Atmospheric science (2)
- Beauty production (2)
- Bhabha (2)
- Climate change (2)
- Collectivity (2)
- Correlation (2)
- Cross section (2)
- Diffraction (2)
- Electroweak Interaction (2)
- Elliptic flow (2)
- Genetics (2)
- Hadronic cross section (2)
- Heavy Ions (2)
- Heavy-ion collisions (2)
- Leptonic, semileptonic & radiative decays (2)
- Muon anomaly (2)
- Particle Correlations and Fluctuations (2)
- Particle decays (2)
- Pb–Pb collisions (2)
- Pion form factor (2)
- RHIC (2)
- Shear viscosity (2)
- Single electrons (2)
- electronic band structure (2)
- photoelectron spectroscopy (2)
- transition-metal oxides (2)
- 900 GeV (1)
- ADHD (1)
- ALICE detector (1)
- Absolute branching fraction (1)
- Angular distribution (1)
- Annihilation (1)
- Anti-nuclei (1)
- Atmospheric chemistry (1)
- Autoimmunity (1)
- B-slope (1)
- BESIII detector (1)
- BRD4 (1)
- Boosted Jets (1)
- Born cross section measurement (1)
- Brain (1)
- CDK9 (1)
- COVID-19 (1)
- CP violation (1)
- Cell therapy (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Charmonia (1)
- Charmonium (-like) (1)
- Clinical trials (1)
- Coalescence (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Comparison with QCD (1)
- Course (1)
- Covariance matrix (1)
- Critical point (1)
- Cross section measurements (1)
- D meson (1)
- D0 and D+ mesons (1)
- Dalitz decay (1)
- Dark photon (1)
- Dark sector (1)
- Data sharing (1)
- Denosumab (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Diagnosis (1)
- D⁰ meson (1)
- Electromagnetic amplitude (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Ewing sarcoma (1)
- Extension study (1)
- FOS: Physical sciences (1)
- FREEDOM (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Flow (1)
- Form factors (1)
- Gene therapy (1)
- GeneMANIA (1)
- Groomed jet radius (1)
- HBT (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hadronization (1)
- Hadrons (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ion collisions (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion (1)
- Hematology (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Higher moments (1)
- Hyperons (1)
- Inclusive branching fraction (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- Invariant Mass Distribution (1)
- Invisible decays (1)
- Ionisation energy loss (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- K0S (1)
- KCGS (1)
- Lepton-Nucleon Scattering (experiments) (1)
- Material budget (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Molecular biology (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiple parton interactions (1)
- NMR spectroscopy (1)
- Net-charge correlations (1)
- Net-charge fluctuations (1)
- Neural network (1)
- Neutrinos (1)
- Nonflow (1)
- Nuclear modification factor (1)
- Oncology (1)
- Osteoporosis (1)
- Outcome (1)
- PYTHIA (1)
- Particle and resonance production (1)
- Particle correlations and fluctuations (1)
- Particle phenomena (1)
- Pb–Pb (1)
- Personalized medicine (1)
- Phase (1)
- Preclinical (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proton (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Quantum chromodynamics (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- R value (1)
- Radiative decay (1)
- Rapidity Range (1)
- Rare decays (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- SARS-CoV-2 (1)
- STAR (1)
- Selection bias (1)
- Semi-leptonic decays (1)
- Single muons (1)
- SoftDrop (1)
- Spin alignment (1)
- Splitting function (1)
- Stem cells (1)
- Strong amplitude (1)
- Systematic Uncertainty (1)
- TR (1)
- Techniques Electromagnetic calorimeters (1)
- Thermal model (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Transversity (1)
- Treatment (1)
- Trigger (1)
- Triple quarkonia (1)
- Vector Boson Production (1)
- W-exchange (1)
- Xenon-based gas mixture (1)
- Y (4260) (1)
- Y states (1)
- accessory proteins (1)
- alleles (1)
- autism spectrum disorder (1)
- autistic disorder (1)
- branching fractions (1)
- cell-free protein synthesis (1)
- center-of-mass energy (1)
- charmed baryon (1)
- charmonium-like states (1)
- chemogenomic set (1)
- combination therapy (1)
- copy number polymorphism (1)
- dE/dx (1)
- decay (1)
- decays (1)
- detector (1)
- dimuon (1)
- diphoton (1)
- drug discovery (1)
- druggable genome (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- e+e− annihilation (1)
- electron-phonon interactions (1)
- electron-positron collision (1)
- electron−phonon interactions (1)
- experimental results (1)
- gene expression (1)
- genes (1)
- genetics (1)
- genome (1)
- genotype (1)
- genotype determination (1)
- global change (1)
- habitat destruction (1)
- hadron spectroscopy (1)
- hadronic events (1)
- heavy ion experiments (1)
- helicity amplitude analysis (1)
- heterostructures (1)
- hheterostructures (1)
- inclusive J/ψ decays (1)
- intrinsically disordered region (1)
- kinase inhibitor (1)
- land use (1)
- luminosity (1)
- neocortex development (1)
- nonstructural proteins (1)
- number of J/ψ events (1)
- p+p collisions (1)
- phenotype (1)
- phenotypic screening (1)
- protein kinase (1)
- quark gluon plasma (1)
- single nucleotide polymorphism (1)
- small molecules (1)
- spectra (1)
- structural proteins (1)
- subventricular zone (SVZ) (1)
- tetraquark (1)
- the allen institute for brain science (1)
- trigger efficiency (1)
- tumor growth (1)
- understudied kinase (1)
- ventricular zone (VZ) (1)
- Λ+c baryon (1)
- Λc⁺ (1)
- Σ hyperon (1)
- ψ(3686) (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1061)
- Frankfurt Institute for Advanced Studies (FIAS) (747)
- Informatik (681)
- Medizin (17)
- Geowissenschaften (6)
- Biochemie, Chemie und Pharmazie (3)
- Geowissenschaften / Geographie (3)
- Informatik und Mathematik (3)
- Hochschulrechenzentrum (2)
- Biodiversität und Klima Forschungszentrum (BiK-F) (1)
The ALICE Collaboration has measured the energy dependence of exclusive photoproduction of J/ψ vector mesons off proton targets in ultra-peripheral p-Pb collisions at a centre-of-mass energy per nucleon pair sNN−−−√=5.02 TeV. The e+e− and μ+μ− decay channels are used to measure the cross section as a function of the rapidity of the J/ψ in the range −2.5<y<2.7, corresponding to an energy in the γp centre-of-mass in the interval 40<Wγp<550 GeV. The measurements, which are consistent with a power law dependence of the exclusive J/ψ photoproduction cross section, are compared to previous results from HERA and the LHC and to several theoretical models. They are found to be compatible with previous measurements.
The ALICE Collaboration has measured the energy dependence of exclusive photoproduction of J/ψ vector mesons off proton targets in ultra-peripheral p-Pb collisions at a centre-of-mass energy per nucleon pair sNN−−−√=5.02 TeV. The e+e− and μ+μ− decay channels are used to measure the cross section as a function of the rapidity of the J/ψ in the range −2.5<y<2.7, corresponding to an energy in the γp centre-of-mass in the interval 40<Wγp<550 GeV. The measurements, which are consistent with a power law dependence of the exclusive J/ψ photoproduction cross section, are compared to previous results from HERA and the LHC and to several theoretical models. They are found to be compatible with previous measurements.
We present a new type of flow analysis, based on a particle-pair correlation function, in which there is no need for an event-by-event determination of the reaction plane. Consequently, the need to correct for dispersion in an estimated reaction plane does not arise. Our method also offers the option to avoid any influence from particle misidentification. Using this method, streamer chamber data for collisions of Ar+KCl and Ar+BaI2 at 1.2 GeV/nucleon are compared with predictions of a nuclear transport model.
The Kinase Chemogenomic Set (KCGS): An open science resource for kinase vulnerability identification
(2019)
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS) is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.
The Kinase Chemogenomic Set (KCGS): an open science resource for kinase vulnerability identification
(2021)
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.
Background: Misconceptions about ADHD stigmatize affected people, reduce credibility of providers, and prevent/delay treatment. To challenge misconceptions, we curated findings with strong evidence base. Methods: We reviewed studies with more than 2000 participants or meta-analyses from five or more studies or 2000 or more participants. We excluded meta-analyses that did not assess publication bias, except for meta-analyses of prevalence. For network meta-analyses we required comparison adjusted funnel plots. We excluded treatment studies with waiting-list or treatment as usual controls. From this literature, we extracted evidence-based assertions about the disorder. Results: We generated 208 empirically supported statements about ADHD. The status of the included statements as empirically supported is approved by 80 authors from 27 countries and 6 continents. The contents of the manuscript are endorsed by 366 people who have read this document and agree with its contents. Conclusions: Many findings in ADHD are supported by meta-analysis. These allow for firm statements about the nature, course, outcome causes, and treatments for disorders that are useful for reducing misconceptions and stigma.
Streamer chamber data for collisions of Ar + KCl and Ar + BaI2 at 1.2 GeV/nucleon are compared with microscopic model predictions based on the Vlasov-Uehling-Uhlenbeck equation, for various density-dependent nuclear equations of state. Multiplicity distributions and inclusive rapidity and transverse momentum spectra are in good agreement. Rapidity spectra show evidence of being useful in determining whether the model uses the correct cross sections for binary collisions in the nuclear medium, and whether momentum-dependent interactions are correctly incorporated. Sideward flow results do not favor the same nuclear stiffness parameter at all multiplicities.
In the past two decades, pions created in the high density regions of heavy ion collisions have been predicted to be sensitive at high densities to the symmetry energy term in the nuclear equation of state, a property that is key to our understanding of neutron stars. In a new experiment designed to study the symmetry energy, the multiplicities of negatively and positively charged pions have been measured with high accuracy for central 132Sn+124Sn, 112Sn+124Sn, and 108Sn+112Sn collisions at E/A = 270 MeV with the SπRIT Time Projection Chamber. While individual pion multiplicities are measured to 4% accuracy, those of the charged pion multiplicity ratios are measured to 2% accuracy. We compare these data to predictions from seven major transport models. The calculations reproduce qualitatively the dependence of the multiplicities and their ratios on the total neutron and proton number in the colliding systems. However, the predictions of the transport models from different codes differ too much to allow extraction of reliable constraints on the symmetry energy from the data. This finding may explain previous contradictory conclusions on symmetry energy constraints obtained from pion data in Au+Au system. These new results call for still better understanding of the differences among transport codes, and new observables that are more sensitive to the density dependence of the symmetry energy.
Background: Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the study conduct had a higher risk of fracture than those who remained enrolled, thereby underestimating the true fracture risk for the entire trial cohort. Thus, we explored the influence of early withdrawals on nonvertebral fracture incidence during the Extension study.
Methods: To understand the potential effect of depletion of susceptible subjects on fracture incidence, we first evaluated subject characteristics in patients who were enrolled in the Extension vs those who were not. We subsequently employed a Kaplan-Meier multiple imputation (KMMI) approach to consider subjects who discontinued as if they remained enrolled with a 0%, 20%, 50%, and 100% increase in fracture risk compared with participants remaining on study.
Results: Extension enrollees were generally similar to nonparticipants in median age (71.9 and 73.1 years, respectively), mean total hip bone mineral density T-score (–1.9 and –2.0, respectively), and probability of fracture risk by Fracture Risk Assessment Tool (FRAX®) at FREEDOM baseline (16.9% and 17.7% for major osteoporotic fracture and 6.7% and 7.4% for hip fracture, respectively). When we assumed a doubled fracture risk (100% increase) after discontinuation in KMMI analyses, nonvertebral fracture rate estimates were only marginally higher than the observed rates for both the crossover group (10.32% vs 9.16%, respectively) and the long-term group (7.63% vs 6.63%, respectively).
Conclusion: The observation of continued denosumab efficacy over 8 years of treatment was robust and does not seem to be explained by depletion of susceptible subjects.
Trial registration: ClincalTrials.gov registration number NCT00523341; registered August 30, 2007
New technologies and therapies designed to facilitate development of personalized treatments are rapidly emerging in the field of biomedicine. Strikingly, the goal of personalized medicine refined the concept of therapy by developing cell-based therapies, the so-called “living drugs”. Breakthrough advancements were achieved in this regard in the fields of gene therapy, cell therapy, tissue-engineered products and advanced therapeutic techniques. The Advanced Therapies in Healthcare symposium, organized by the Clinical Research Center Department of Sidra Medicine, in Doha, Qatar (October 2017), brought together world-renowned experts from the fields of oncology, hematology, immunology, inflammation, autoimmune disorders, and stem cells to offer a comprehensive picture of the status of worldwide advanced therapies in both pre-clinical and clinical development, providing insights to the research phase, clinical data and regulatory aspects of these therapies. Highlights of the meeting are provided in this meeting report.